Scholarlink

<p>Osteosarcoma lacks effective molecular targets, and the biological role of MAT2A in this disease remains unclear. Here we show that MAT2A drives osteosarcoma progression by increasing the transcription of the downstream gene <i>PARN</i>. MAT2A interacts with the transcription factor SRF, promotes its SUMO-dependent stabilization in the nucleus, and enhances its ability to activate PARN. A catalytically inactive MAT2A mutant retains this function, indicating a SAM-independent mechanism. MAT2A also elevates aerobic glycolysis in osteosarcoma cells through the PARN–PI3K–AKT pathway, while pharmacological inhibition of MAT2A reduces glycolysis, SRF and PARN expression, and tumor growth in vitro and in vivo. These findings identify a previously unrecognized regulatory mechanism linking MAT2A to transcriptional control and metabolic reprogramming, and highlight MAT2A as a promising therapeutic target for osteosarcoma.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

MAT2A enhances PARN transcription via SRF to accelerate glycolysis and drive malignant progression in osteosarcoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月13日

查看全文
  • Zhinan Ren,
  • Haoming Chen,
  • Qi Qiao,
  • Zehao Xie,
  • Jianhua Hu,
  • Canjun Zeng,
  • Yi Shen,
  • Runguang Li

摘要

Osteosarcoma lacks effective molecular targets, and the biological role of MAT2A in this disease remains unclear. Here we show that MAT2A drives osteosarcoma progression by increasing the transcription of the downstream gene PARN. MAT2A interacts with the transcription factor SRF, promotes its SUMO-dependent stabilization in the nucleus, and enhances its ability to activate PARN. A catalytically inactive MAT2A mutant retains this function, indicating a SAM-independent mechanism. MAT2A also elevates aerobic glycolysis in osteosarcoma cells through the PARN–PI3K–AKT pathway, while pharmacological inhibition of MAT2A reduces glycolysis, SRF and PARN expression, and tumor growth in vitro and in vivo. These findings identify a previously unrecognized regulatory mechanism linking MAT2A to transcriptional control and metabolic reprogramming, and highlight MAT2A as a promising therapeutic target for osteosarcoma.